Key result
Long non-coding RNAs emerge as critical regulators of vascular inflammation and potential cardiovascular therapeutic targets.
Why the study?
Knowledge of the mechanisms by which long non-coding RNAs control cardiovascular disease-related gene expression and cell signaling in vascular inflammation is limited.
Long non-coding RNAs are emerging as important regulators of vascular inflammation and hold promise as novel biomarkers and therapeutic targets in cardiovascular disease.
Clinical use of long non-coding RNA biomarkers remains premature; leaves open their therapeutic potential pending prospective trials.
Less than 2% of the genome encodes for proteins. Accumulating studies have revealed a diverse set of RNAs derived from the non-coding genome. Among them, long non-coding RNAs (lncRNAs) have garnered widespread attention over recent years as emerging regulators of diverse biological processes including in cardiovascular disease (CVD). However, our knowledge of their mechanisms by which they control CVD-related gene expression and cell signaling pathways is still limited. Furthermore, only a handful of lncRNAs has been functionally evaluated in the context of vascular inflammation, an important process that underlies both acute and chronic disease states. Because some lncRNAs may be expressed in cell- and tissue-specific expression patterns, these non-coding RNAs hold great promise as novel biomarkers and as therapeutic targets in health and disease. Herein, we review those lncRNAs implicated in pro- and anti-inflammatory processes of acute and chronic vascular inflammation. An improved understanding of lncRNAs in vascular inflammation may provide new pathophysiological insights in CVD and opportunities for the generation of a new class of RNA-based biomarkers and therapeutic targets.
No takes yet. Share an insight, caveat, or question.
Haemmig et al. (2018) conducted a review in Vascular inflammation and cardiovascular disease. Long non-coding RNAs (lncRNAs) was evaluated. Long non-coding RNAs are emerging as critical regulators of acute and chronic vascular inflammation, offering potential as novel biomarkers and therapeutic targets for cardiovascular disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: